T-Therapeutics (a next-generation T-cell engager and immunology biotech firm founded by Prof. Allan Bradley) is led by Theodora Harold, who was appointed as Chief Executive Officer. She brings over two decades of biotechnology executive leadership experience, managing capital raises and clinical-stage oncology and immunology development pipelines.